Plain-English translation of NCT02016248 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a newer form of radiation therapy called stereotactic body radiotherapy (SBRT) as a potential replacement for a traditional invasive treatment called high dose rate brachytherapy. If you have aggressive or high-risk prostate cancer, you would receive standard radiation therapy to your whole pelvis, plus five short, high-dose treatments that are aimed very precisely at your prostate using imaging and tiny gold markers to track movement. The goal is to see if this method works as well as the traditional approach while causing fewer side effects.
Traditional radiation boosts for aggressive prostate cancer involve placing needles inside the prostate, which can be uncomfortable and carries risks. Researchers want to know whether this newer, needle-free approach can deliver the same cancer-fighting power with better safety and quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive a combination of standard external radiation therapy to your pelvis plus five focused radiation boosts over a short period. After treatment ends, you would have regular follow-up visits over five years—including physical exams, blood tests to check your PSA level, imaging scans if needed, and questionnaires about any side effects and how the treatment affects your urinary and sexual function. The research team will monitor you closely to ensure the treatment is working and to catch any side effects early.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States